Craft

GenScript

Stock Price

$23.2

2023-11-10

Market Capitalization

$49.2 B

2023-11-10

Revenue

$625.7 M

FY, 2022

GenScript Summary

Company Summary

Overview
Genscript Biotech is a biotech company focusing on early drug discovery and development services. It offers DNA synthesis technology, peptide synthesis, solubility testing, recombinant protein expression, antibody sequencing and production, etc. The company operates through four platforms including the life science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the global cell therapy platform, and the industrial synthesis biological product platform.
Type
Public
Status
Active
Founded
2002
HQ
Nanjing, CN | view all locations
Website
https://www.genscript.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Zhu Li

    Zhu Li, Executive Director, Chief Strategy Officer

  • Wang Ye

    Wang Ye, Executive Director, President

    • Meng Jiange

      Meng Jiange, Executive Director, Chairman

      • Zhang Fangliang

        Zhang Fangliang, Executive Director

        Operating MetricsView all

        Business Segments

        4

        FY, 2022

        Countries

        100

        FY, 2022

        Remaining Performance Obligations

        $43.7M
        87.2%

        FY, 2022

        LocationsView all

        7 locations detected

        • Nanjing, Jiang Su Sheng HQ

          China

          28 Yongxi Road

        • Piscataway, NJ

          United States

          860 Centennial Ave

        • Tokyo, Tokyo

          Japan

          Ism Kanda 4F, 48 Kanda Higashi Matsushita-cho, Chiyoda-ku

        • Rijswijk, ZH

          Netherlands

          Treubstraat 1, 1st floor

        • Singapore

          Singapore

          164 Kallang Way, #06-12

        • Seoul, Seoul

          Korea (Republic of)

          IKP building #709, 7, Heolleung-ro

        and 1 others

        GenScript Financials

        Summary Financials

        Revenue (FY, 2022)
        $625.7M
        Gross profit (FY, 2022)
        $377.5M
        Net income (FY, 2022)
        ($428.0M)
        Cash (FY, 2022)
        $1.3B
        EBIT (FY, 2022)
        ($445.4M)
        Enterprise value
        $48.3B

        Footer menu